Posted inGastroenterology Infectious Diseases news

Proton Pump Inhibitors and Clostridioides difficile Infection: A Comprehensive Meta-Analysis of Randomized Controlled Trials Reveals No Increased Risk

This systematic review and meta-analysis of randomized controlled trials finds no significant association between proton pump inhibitor use and increased risk of Clostridioides difficile infection, challenging earlier observational data and supporting their safety in clinical practice when appropriately prescribed.
Evaluating the Safety and Immunogenicity of the Adjuvanted RSVPreF3 Vaccine in High-Risk Transplant Recipients: A Critical Analysis of an Interventional Cohort Study
Posted inInfectious Diseases news Respiratory Specialties

Evaluating the Safety and Immunogenicity of the Adjuvanted RSVPreF3 Vaccine in High-Risk Transplant Recipients: A Critical Analysis of an Interventional Cohort Study

This study assesses the safety and immune response of an adjuvanted RSVPreF3 vaccine in adult allogeneic hematopoietic cell and lung transplant recipients, highlighting modest antibody responses but robust CD4+ T-cell activation, supporting vaccination benefits amidst immunocompromised risks.
Optimizing Empiric Antibiotic Selection in Hospitalized Patients with Skin and Abdominal Infections: Insights from the INSPIRE 3 and 4 Cluster Randomized Clinical Trials
Posted inGeneral Surgery Infectious Diseases Specialties

Optimizing Empiric Antibiotic Selection in Hospitalized Patients with Skin and Abdominal Infections: Insights from the INSPIRE 3 and 4 Cluster Randomized Clinical Trials

The INSPIRE 3 and 4 trials demonstrate that computerized provider order entry (CPOE) prompts with patient-specific MDRO risk estimates, combined with education and feedback, significantly reduce empiric extended-spectrum antibiotic use in skin, soft tissue, and abdominal infections without compromising safety.
Sequential Pegylated Interferon after Bepirovirsen Lowers Relapse Risk in Chronic Hepatitis B: Insights from the B-Together Trial
Posted inClinical Updates Infectious Diseases news Specialties

Sequential Pegylated Interferon after Bepirovirsen Lowers Relapse Risk in Chronic Hepatitis B: Insights from the B-Together Trial

The B-Together phase IIb study demonstrates that sequential therapy with bepirovirsen followed by pegylated interferon-α-2a reduces post-treatment relapse in chronic hepatitis B patients on stable nucleos(t)ide analogue therapy, with enhanced responses in patients with lower baseline HBsAg levels.